Literature DB >> 18848837

Molecular determinants of angiotensin II type 1 receptor functional selectivity.

Mark Aplin1, Marie Mi Bonde, Jakob Lerche Hansen.   

Abstract

The angiotensin AT(1) receptor is an important pharmacological target in the treatment of cardiovascular disorders, such as hypertension, diabetic nephropathy, cardiac hypertrophy, arrhythmia and failure. Simultaneously, the AT(1) receptor has emerged to be a prominent model for the emerging concept that receptors may attain multiple active states with differentiated functional outcomes. Two major signalling pathways are employed by the AT(1) receptor, namely 1) the canonical G(q) protein-dependent activation of inositol phosphate turnover and intracellular calcium release, and 2) G protein-independent recruitment of beta-arrestin-scaffolded signalling complexes that activate protein kinase pathways. Different states of receptor activation with preference for individual downstream pathways (functional selectivity) have been demonstrated in mutational studies of the AT(1) receptor and by pharmacological probing with analogues of angiotensin II. These studies also provide clues about the conformational changes that underlie different functional outcomes. In this review, we evaluate current knowledge of the molecular determinants of AT(1) receptor activation, which may distinguish G protein-dependent and -independent behaviour. While G protein activation is known to be detrimental, G protein-independent signalling by the AT(1) receptor has been associated with phenotypes such as cell survival and renewal, regulation of cardiac contraction and cell migration. It is therefore currently hypothesized that selective blockade of G protein actions and simultaneous activation of G protein-independent signalling will prove to be a feasible strategy for improved cardiovascular therapy. The pharmacological perspectives of functional selectivity by receptors, such as the AT(1) receptor, urge the elucidation of molecular mechanisms that govern disparate signalling events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848837     DOI: 10.1016/j.yjmcc.2008.09.123

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  24 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.

Authors:  Jérôme Cabana; Brian Holleran; Richard Leduc; Emanuel Escher; Gaétan Guillemette; Pierre Lavigne
Journal:  J Biol Chem       Date:  2015-05-01       Impact factor: 5.157

Review 4.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact.

Authors:  Terry Kenakin; Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2012-02-15       Impact factor: 84.694

5.  Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists.

Authors:  Gitte L Christensen; Christian D Kelstrup; Christina Lyngsø; Uzma Sarwar; Rikke Bøgebo; Søren P Sheikh; Steen Gammeltoft; Jesper V Olsen; Jakob L Hansen
Journal:  Mol Cell Proteomics       Date:  2010-04-02       Impact factor: 5.911

6.  Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide.

Authors:  Jun Liu; Gina L C Yosten; Hong Ji; Dan Zhang; Wei Zheng; Robert C Speth; Willis K Samson; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

7.  Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.

Authors:  Danielle da C Silva; Vinicius G Maltarollo; Emmanuela Ferreira de Lima; Karen Cacilda Weber; Kathia M Honorio
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

8.  Biased agonism.

Authors:  Terry Kenakin
Journal:  F1000 Biol Rep       Date:  2009-11-26

9.  Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.

Authors:  Marie Mi Bonde; Jonas Tind Hansen; Samra Joke Sanni; Stig Haunsø; Steen Gammeltoft; Christina Lyngsø; Jakob Lerche Hansen
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  AT1 mutations and risk of atrial fibrillation based on genotypes from 71,000 individuals from the general population.

Authors:  Sarah C W Marott; Børge G Nordestgaard; Gorm B Jensen; Anne Tybjaerg-Hansen; Marianne Benn
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.